Sanofi's Dupixent falls short in phase 3 chronic spontaneous urticaria trial

Sanofi's Dupixent falls short in phase 3 chronic spontaneous urticaria trial

Source: 
Pharmaforum
snippet: 

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don’t respond to the only approved biologic treatment, Novartis/Roche’s Xolair.